Invasive Hemodynamic Changes Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cardiovasc Ther. 2024 May 27:2024:2735577. doi: 10.1155/2024/2735577. eCollection 2024.

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to lower incident heart failure (HF) and HF hospitalizations, but the mechanisms of benefit in relation to invasive hemodynamics remain unclear. Using PRISMA guidelines, we systematically reviewed multiple online databases for randomized trials evaluating the effect of SGLT2i on invasive hemodynamics. Rest and peak exercise invasive hemodynamics were measured via right heart catheterization pre- and postintervention. Random effects model meta-analysis at a 95% confidence interval was done using RevMan 5.0. A total of 3 studies with a total of 145 patients were included in the meta-analysis. SGLT2i was significantly associated with a reduction in pulmonary capillary wedge pressure at rest and peak exercise. Similarly, SGLT2i reduced mean pulmonary artery pressure at rest and peak exercise, respectively; however, this was not statistically significant. This hypothesis-generating study offers mechanistic insights into the central hemodynamic effects of SGLT2i underpinning the HF benefits of SGLT2i.

Keywords: invasive hemodynamics; mean pulmonary artery pressure; pulmonary capillary wedge pressure; right heart catheterization; sodium-glucose cotransporter-2 inhibitors.

Publication types

  • Systematic Review
  • Meta-Analysis

MeSH terms

  • Aged
  • Cardiac Catheterization
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / physiopathology
  • Female
  • Heart Failure* / diagnosis
  • Heart Failure* / drug therapy
  • Heart Failure* / physiopathology
  • Hemodynamics* / drug effects
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Wedge Pressure / drug effects
  • Randomized Controlled Trials as Topic*
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
  • Treatment Outcome

Substances

  • Sodium-Glucose Transporter 2 Inhibitors